Blueprint Medicines (BPMC) Misses Q3 EPS by 37c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Nvidia underperforms peers as report sparks rack delay worries
• Morgan Stanley Resumes Gap, Inc. (GAP) at Equalweight